Aptamer-based Proteomic Signature of Intensive Phase Treatment Response in Pulmonary Tuberculosis

Tuberculosis (Edinburgh, Scotland) (Impact Factor: 2.71). 05/2014; 94(3). DOI: 10.1016/


New drug regimens of greater efficacy and shorter duration are needed for tuberculosis (TB) treatment. The identification of accurate, quantitative, non-culture based markers of treatment response would improve the efficiency of Phase 2 TB drug testing.

In an unbiased biomarker discovery approach, we applied a highly multiplexed, aptamer-based, proteomic technology to analyze serum samples collected at baseline and after 8 weeks of treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in a Centers for Disease Control and Prevention (CDC) TB Trials Consortium Phase 2B treatment trial.

We identified protein expression differences associated with 8-week culture status, including Coagulation Factor V, SAA, XPNPEP1, PSME1, IL-11 Rα, HSP70, Galectin-8, α2-Antiplasmin, ECM1, YES, IGFBP-1, CATZ, BGN, LYNB, and IL-7. Markers noted to have differential changes between responders and slow-responders included nectin-like protein 2, EphA1 (Ephrin type-A receptor 1), gp130, CNDP1, TGF-b RIII, MRC2, ADAM9, and CDON. A logistic regression model combining markers associated with 8-week culture status revealed an ROC curve with AUC=0.96, sensitivity=0.95 and specificity=0.90. Additional markers showed differential changes between responders and slow-responders (nectin-like protein), or correlated with time-to-culture-conversion (KLRK1).

Serum proteins involved in the coagulation cascade, neutrophil activity, immunity, inflammation, and tissue remodeling were found to be associated with TB treatment response. A quantitative, non-culture based, five-marker signature predictive of 8-week culture status was identified in this pilot study.

22 Reads
  • Source
    • "Detection of systemic heme oxygenase-1 (HO-1) levels showed some promise, with a larger number of patients who were successfully treated showing decreased HO-1 levels, and levels remaining unchanged in five patients who were culture positive at the end of 6 mo of treatment (Andrade et al., 2013). Nahid et al. (2014) measured hundreds of proteins in serum samples from 39 patients and identified a five-marker signature (IL-11, R, 2-Antiplasmin, PSME1, and SAA) that predicted conversion with an estimated 80 ± 11% sensitivity and 80 ± 7% specificity upon internal cross-validation. All of these studies require confirmation in independent cohorts and—most importantly—correlation with relapse-free cure. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The world is in need of more effective approaches to controlling tuberculosis. The development of improved control strategies has been hampered by deficiencies in the tools available for detecting Mycobacterium tuberculosis and defining the dynamic consequences of the interaction of M. tuberculosis with its human host. Key needs include a highly sensitive, specific nonsputum diagnostic; biomarkers predictive of responses to therapy; correlates of risk for disease development; and host response-independent markers of M. tuberculosis infection. Tools able to sensitively detect and quantify total body M. tuberculosis burden might well be transformative across many needed use cases. Here, we review the current state of the field, paying particular attention to needed changes in experimental paradigms that would facilitate the discovery, validation, and development of such tools.
    Journal of Experimental Medicine 10/2015; 212(11). DOI:10.1084/jem.20151468 · 12.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients vary considerably in their response to treatment of pulmonary tuberculosis. Although several studies have indicated that adverse outcomes are more likely in those patients with delayed sputum sterilization, few tools are available to identify those patients prospectively. In this study, multivariate models were developed to predict the response to therapy in a prospectively recruited cohort of 42 HIV-uninfected subjects with drug-sensitive tuberculosis. The cohort included 2 subjects whose initial response was followed by drug-sensitive relapse. The total duration of culture positivity was best predicted by a model that included sputum M. tuberculosis antigen 85 concentration on Day 14 of therapy, days-to-positive in BACTEC on Day 30, and the baseline radiographic extent of disease (R = 0.63). A model in which quantitative AFB microscopy replaced BACTEC also performed adequately (R = 0.58). Both models predicted delayed clearance of bacilli in both relapses (> 85th percentile of all subjects) using information collected during the first month of therapy. Stratification of patients according to anticipated response to therapy may allow TB treatment to be individualized, potentially offering superior outcomes and greater efficiency in resource utilization, and aiding in the conduct of clinical trials.
    American Journal of Respiratory and Critical Care Medicine 04/2000; 161(4 Pt 1):1076-80. DOI:10.1164/ajrccm.161.4.9903087 · 13.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tuberculosis differs from most other bacterial infectious diseases by a very long duration of combination antibiotic therapy required to achieve relapse-free cure. While the standard recommended "short-course" treatment length for tuberculosis is 6 months, the World Health Organization recommends duration of 20 months for the treatment of patients with multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (XDR-TB). Apart from the long duration of antituberculosis therapy, treatment of M/XDR-TB is very expensive and often associated with adverse drug events. The optimal duration for treatment of tuberculosis likely differs between individuals and depends on a variety of variables, such as the extent of the disease, the immune status of the host and the virulence and the drug-resistance of the causative strain of M. tuberculosis. Some patients with M/XDR-TB may have to be treated with currently available anti-tuberculosis drug regimens for more than 20 months while much shorter treatment durations may be possible to achieve cure for the majority of patients with M/XDR-TB. Personalization of the duration of treatment for tuberculosis, especially for patients with M/XDR-TB, would be highly desired. In recent years much progress has been made in the identification of bio-signatures that could eventually lead to individual recommendations for the duration of antituberculosis therapy for tuberculosis patients. This pulmonary perspective reviews the knowledge on clinical and radiological scores, host- and pathogen disease-related profiles, molecules and signatures that are currently explored as biomarkers to personalize the duration of therapy in tuberculosis.
    American Journal of Respiratory and Critical Care Medicine 06/2014; DOI:10.1164/rccm.201402-0363PP · 13.00 Impact Factor
Show more